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Background: The effects of Hepatitis B virus (HBV) rtA181T/sW172* mutation on viral replication and pathogenicity
was concerned recently. This study aimed to investigate the biological characteristics of rtA181T/sW172* mutant
strain of HBV in animal model.
Methods: The rtA181T/sW172* mutant plasmid was constructed using the pHBV4.1 (wild type HBV) as a template.
The wild and mutant HBV replication mouse models were established utilizing a hydrodynamic technique. The
titers of hepatitis B surface antigen (HBsAg), hepatitis B e antigen, and HBV DNA in serum, and the levels of HBsAg,
hepatitis B core antigen(HBcAg), HBV DNA replication intermediates (HBV DNA RI) and HBV RNA in liver were
measured after 1, 3, 5, 7, 10, 12 and 15 days of plasmid injection.
Results: In wild-type HBV replication mouse model, serum HBsAg was high on day 1, 3, and 5, but became lower
since day 7; while in mutant HBV mouse model, serum HBsAg was always at very low level. In liver tissues, HBV
DNA RI of wild type HBV was detected on day 1 after transfection. The level subsequently peaked on day 3,
gradually declined after day 5, and was almost undetectable on day 10. However, the HBV DNA RI levels of the
mutant strain were always higher and lasted longer until day 15. Consistently, the expression levels of HBsAg and
HBcAg in liver of the mutant group were significantly increased.
Conclusions: In the case of the HBV rtA181T/sW172* mutation, the secretion of serum HBsAg was impaired,
whereas HBV DNA replication and HBsAg/HBcAg expression were increased in liver. These results suggest that the
mutation can impair HBsAg secretion, and may cause the accumulation of viral core particles in liver.
Keywords: Hepatitis B virus, rtA181T/sW172* mutation, Transcription and replication, Hepatitis B surface antigen,
Secretion defect, Drug sensitivityBackground
More than 350 million people are chronically infected
with HBV worldwide, which leads to about 1 million
death per year [1]. There are currently two classes of
antiviral agents for chronic hepatitis B (CHB): nucleos(t)
ide analogs (NAs) directly inhibiting HBV DNA replica-
tion and interferon-based therapies that may modulate
the host immune response as well as viral replication.
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reproduction in any medium, provided the orhave contributed to the increased incidence of drug re-
sistant cases.
HBV, a member of the hepadnavirus family, is an
enveloped virus that contains a partially-double stranded
circular DNA about 3.2 kb in length. HBV DNA has a
very compact coding organization with four partially
overlapping open reading frames (ORFs), including ORF
P, X, S and C [2]. Among them, ORF P that encodes the
RT (reverse transcriptase) domains of the polymerase
overlaps completely with the ORF S that encodes HBV
surface proteins [3]. The HBV surface proteins, including
the S protein (226 amino acids), the M protein (281
amino acids), and the L protein (389–400 amino acids),
are encoded by one long open reading frame that utilizes
three different start codons and the same stop codon.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Time-dependent HBV antigen and HBV DNA
expression in mice serum after hydrodynamic transfection
in vivo. Mice were injected with 10μg pHBV4.1 (Wt) or pHBV rtA181T/
sW172* (Mut) respectively. At different time points, HBsAg (A) and
HBeAg (B) in the serum were measured by ELISA, and HBV DNA (C) in
the serum were detected by quantitative real-time PCR. The mean
HBsAg, HBeAg and DNA levels plus standard deviation (indicated by
error bars) from three independent analyses are shown (* P<0.001).
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envelopment of nucleocapsid with subsequent assembly
of virion, and assembly into empty subviral particles that
are secreted in great excess over HBV virions collectively
referred to as hepatitis B surface antigen [4]. The surface
proteins also are targets of the host cellular immune sys-
tem. The extent to which the host recognizes viral anti-
gens presented by infected cells determines whether an
infection will be acute or chronic.
The HBV rtA181T/sW172* mutant strain researched
in this study is that the rtA181T mutation in the viral
polymerase encodes a stop codon in the overlapping sur-
face gene at amino acid 172 (sW172) resulting in trunca-
tion of the last 55 amino acids of the C-terminal
hydrophobic region of the surface proteins. The rtA181T
mutation causes drug resistance to adefovir (ADV) clin-
ically [5]. It has been revealed in cell culture that the
mutation results in a decreased susceptibility to lamivu-
dine (LAM), ADV, and tenofovir, while remaining sensi-
tive to entecavir (ETV)[6]. The rtA181T/sW172*
mutation also reduces the typical extent of virological
breakthrough [4]. Previous studies in vitro also demon-
strated that the rtA181T/sW172* mutation may impair
HBsAg secretion, and may be an oncogenic potential
factor leading to advanced hepatocellular carcinoma
(HCC) [7]. However, the effect of the rtA181T/sW172*
mutation on HBV virology in vivo remains unclear. So it is
thus necessary to study the biological characteristics of the
HBV rtA181T/sW172* mutation in vivo environment.
In this study, a mouse model for the replication of the
HBV rtA181T/sW172* mutant was established using a
hydrodynamic-based procedure [8]. The effect of the
rtA181T/sW172* mutation on HBV transcription, repli-
cation and HBsAg secretion were investigated.
Results
Expression levels of HBsAg and HBeAg in mouse serum
After injection of the wild type (pHBV4.1) or the mutant
(pHBVrtA181T/sW172*) plamids, the level of serum
HBsAg in mice injected with the wild type plasmid was
very high (OD>2.4) on day 1, 3, and 5, and became low
(OD<0.2) since day 7. However, the level of serum
HBsAg in mice injected with the mutant plasmid was al-
ways very low (OD<0.4, Figure 1A). In contrast, serum
HBeAg had similar patterns between two groups
(Figure 1B).
HBV-DNA level in mouse serum
Compared to wild type, the rtA181T/sW172* mutant
strain showed an approximately 0.8 log reduction on day
1, 2.6 log reduction on day 3, 1.5 log reduction on day 5,
and 0.7 log reduction on day 7 in serum HBV DNA
titers. The serum HBV DNA levels of the mutant strain
were always lower than that of wild type. The differencewas significant on day 1, 3, 5 and 7, respectively
(Figure 1C). Since day 10, viral loads decreased to very
low level for both two groups.
HBV RNA transcription level in mouse liver
In order to investigate the transcriptional character of
the HBV rtA181T/sW172* mutant strain, HBV RNA
levels in mouse liver were evaluated by northern blotting
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mice injected with the wild type HBV plasmid, the level
of the 3.5kb HBV mRNA peaked on day 3, significant
reduced on day 5, and became almost undetectable on
day 7 (Figure 2A). But for mice injected with the mutant
HBV plasmid, the 3.5kb HBV mRNA was detected on day
1, reached peak on day 3–5, decreased on day 7, and still
remained detectable until day 15 (Figure 2A). At most of
the time points, the 3.5kb HBV mRNA level in mice
injected with the mutant HBV plasmid was higher than
that of mice injected with the wild type plasmid
(Figure 2B). Meanwhile, compared to mice received injec-
tions of the wild type plasmid, the levels of HBV S-mRNA
and C-mRNA of mice injected with the mutant plasmid
were increased as detected by qPCR (Figure 2C, D). The
values shown were the average of three experiments
(means plus standard deviation).
Levels of HBV DNA replication intermediates in mouse
liver
In the mouse model for wild type HBV replication, HBV
DNA replication intermediates were detectable on day 1,
became abundant on day 3, decreased on day 5, and
were very weak on day 7 (Figure 3A). However, the HBV
DNA replication intermediates levels of the HBV mutantFigure 2 Time-dependent viral transcription after hydrodynamic tran
blotting, and GAPDH transcript was used as an internal control for RNA loa
automatically by the Quantity-One software (Bio-Rad); C or D: The total lev
and the mean value of Wt of day 1 was defined as 1.rtA181T/sW172* were detectable from day 1 to day 15
and peaked on day 3 and day 5 (Figure 3B). Compared
to the wild type HBV, the HBV DNA replication inter-
mediates levels of mutant HBV in mouse liver were
higher and also lasted longer (Figure 3A, B).Expression levels of HBsAg and HBcAg in mouse liver
Animals were sacrificed and livers were embedded and
sectioned at different time points after injection. As
shown in Figure 4, HBsAg staining can only be detected
in the cytoplasm (4A), while HBcAg was present in the
nuclei and cytoplasm of the hepatocytes with most ex-
pression found in the nuclei (4B). And all the positive
cells were stained brown. HBsAg-positive cells in mice
infected with wild type HBV were abundant on day 3.
The number of positive cells significantly reduced on
day 5, and positive cells became scarce in liver on day 7.
In contrast, HBsAg stained hepatocytes in sections from
the mutant group accumulated in abundance from day 3
to day5, and diminished on day 7 (4A). Meanwhile, the
expression pattern of HBcAg was similar to that of
HBsAg (4B). It also revealed that the expression level of
HBsAg and HBcAg in the livers of the mutant group
was increased compared with wild type.sfection in vivo. A: HBV RNA of mice liver were detected by Northern
ding per lane; B: The 3.5-kb HBV mRNA was quantitatively calculated
els of HBV S-mRNA or C-mRNA in mouse liver were detected by qPCR,
Figure 3 Time-dependent viral replication after hydrodynamic
transfection in vivo. Mice were injected hydrodynamically with
10μg pHBV4.1 (Wt) or pHBV rt A181T/sW172 (Mut) respectively, and
were sacrificed at different time points. A: HBV DNA replication
intermediates of mice livers were detected by Southern blotting. B:
Quantitative analysis of HBV DNA replication intermediates. The
levels of HBV DNA replication intermediates in Wt group on day 1
were defined as 1.
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mutant HBV in vivo
To analyze the effects of the HBV rtA181T/sW172* mu-
tation on antiviral drug resistance, the inhibitory effects
of four anti-HBV drugs on replication of the wild type
and mutant HBV were compared. For wild type HBV,
viral replication was inhibited by LAM, ADV, ETV and
telbivudine (LdT) for 6.19-fold, 9.57-fold, 9.82-fold and
5.01-fold, respectively (Figure 5A, B). For the mutant
HBV, viral replication was inhibited by LAM, ADV, ETV
and LdT for 3.83-fold, 7.80-fold, 9.80-fold and 3.27-fold,
respectively (Figure 5A, B). Compared to wild type HBV,
the rtA181T mutant remained sensitive to ETV, but had
a reduced susceptibility to LAM, ADV and LdT, as the
inhibition effects decreased about 2.36-fold, 1.77-fold
and 1.74-fold (Figure 5).Materials and methods
Ethics statement
This study obtained ethics approval from the Laboratory
Animal ethics committee of Sichuan University.Plasmid
The wild type pHBV4.1 (pHBVwt [wt, wild-type]) is an
HBV replication competent plasmid which contains 1.3
copies of the HBV genome (subtype ayw) [9] and is cap-
able of HBV transcription, replication, and expression
both in vitro and in vivo [10]. A point mutation
(rtA181T) in the RT region replacing Alanine (A) 181
with Threonine (T) was introduced via site-directed mu-
tagenesis (QuikChange mutagenesis kit, Stratagene)
according to the manufacturer’s instructions using the
forward primer: 5'-CAGCCCGTTTCTCCTGACTCAG
TTTACTAGTGC-3' and the reverse primer: 5'-GCAC
TAGTAAACTGAGTCAGGAGAAACGGGCTG-3'. The
resulting mutant plasmid was named pHBVmut (mut,
mutation type). This mutation also created a prema-
ture stop codon that replaces amino acid 172W of
HBsAg.
A mouse model for HBV replication
Male BALB/C mice that were maintained in specific-
pathogen-free (SPF) conditions and weighted 18-20g
were purchased from the Laboratory Animal Center at
Sichuan University. All mice received humane care
under the Institutional Review Board in accordance with
Animal Protection Art of Sichuan University.
In order to establish the mouse model for HBV repli-
cation, 10μg of pHBV4.1 or pHBVmut plasmids diluted
in phosphate-buffered saline (PBS) was injected into the
mouse tail vein in a volume of 10% of the body weight
(v/w) within 5–8 seconds (hydrodynamic in vivo trans-
fection)[11]. Mice were sacrificed after 1, 3, 5, 7, 10, 12
and 15 days of DNA injection. Liver tissues and blood
were collected.
HBV antigen assays
Serum HBsAg and HBeAg were measured using ELISA
kits following the manufacturer’s protocol (Shanghai
Shiye Kehua Company, China). Absorbance was mea-
sured in a microtiter plate reader with dual-wave length
measurement (450/645nm).
Formalin-fixed liver tissues from the treated mice were
embedded in paraffin. HBsAg and HBcAg were detected
by immunohistochemical staining using specific anti-
bodies against HBsAg (mouse anti-HBs, Thermol) and
HBcAg (rabbit anti-HBc, NEOMARKERS), respectively.
All procedures for the immunological detections of these
antigens were performed according to the manufac-
turer's protocol.
Analysis of liver HBV RNA
Mouse liver tissues were mechanically pulverized in li-
quid nitrogen, and total RNA was extracted from pulver-
ized tissues using Trizol reagent following the
manufacturer’s instructions (Invitrogen, USA). The 30
Figure 4 The expression of HBsAg (A) and HBcAg (B) immunohistochemistry detection in liver tissue sections. Mice liver sections on day
3, 5 and 7 after transfection were detected using specific antibody. The positive expressions were stained brown as shown by black arrow, which
were magnified 400 times in the top right corner of these pictures (100×original magnification).
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hybridization using probes for both GAPDH and HBV,
with the GAPDH serving as an internal control [12].
Analysis of liver HBV DNA replication intermediates
Frozen liver tissues were mechanically pulverized in li-
quid nitrogen and HBV DNA replication intermediates
were isolated from one hundred and twenty micrograms
of liver tissue powder as described previously [12]. AndFigure 5 Drug susceptibility test of antiviral drugs on HBV replication
intermediates were detected by southern blotting in the mouse model tre
(ETV) and telbivudine (LdT), respectively. B: The relative levels of HBV DNA
The levels of HBV DNA replication intermediates in NS treated wild-type gr
of treated groups were calculated accordingly.these HBV DNA replication intermediates were diluted
to 30 μl with TE buffer. All of viral replication inter-
mediates was analyzed by Southern blotting as previ-
ously described [8]. Membranes were hybridized with
digoxigenin-labeled (Roche Applied Science) HBV ayw
genomic DNA to detect HBV sequences [13]. The levels
of HBV DNA replication intermediates were calculated
by the Quantity One software according to manufac-
turer’s instructions (Bio-Rad).using the HBV replication mouse model. A: HBV DNA replication
ated with NS (control), lamivudine (LAM), adefovir (ADV), entecavir
replication intermediates in the mouse model among different groups.
oup and mutant mice were set to 1 respectively, and the relative levels
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time PCR
100 μL of mice serum predigested with DNaseIwas used
for the detection of HBV DNA by quantitative real-time
PCR (qPCR) using a diagnostic kit for quantification of
HBV-DNA (Da An Gene, Guangzhou, China).
The qPCR analysis of HBV RNA in mice liver was per-
formed using the LightCycler system (Bio-Rad). Amplifi-
cation was carried out in two steps: denaturation at 95°C
for 5 sec and annealing at 60°C for 5 sec. Also the num-
ber of PCR cycles was 30 times. To distinguish specific
from nonspecific cDNA products, a melting curve was
obtained at the end of each run. Data were normalized
against the GAPDH level in each sample. HBV RNA was
detected using the C region primer pairs (forward: 5'-
CTGGGTGGGTGTTAATTTGG-3', reverse: 5'-TAAGC
TGGAGGAGTGCGA AT-3') and the S region primer
pairs (forward: 5'-CTCCAATCACTCACCAACCT-3', re-
verse: 5'-TCCAGA AGA ACCAACAAG AAG A-3'). The
primers for GAPDH (internal control) were: forward: 5'-
AACTTTGGCATTGTGGAAGG-3', reverse: 5'-ACACA
TTGGGGGTAGGAACA-3'. (All primers were synthe-
sized by Invitrogen, Shanghai, China).
Antiviral treatment utilizing NAs
Twenty-four hours after hydrodynamic injection, nucleo-
side analogues, including lamivudine (GlaxoSmithKline,
250mg/kg/d), adefovir (GlaxoSmithKline, 15mg/kg/d),
entecavir (Bristol-Myers Squibb, 0.075mg/kg/d), and tel-
bivudine (LdT, NOVARTIS, 1800mg/kg/d), and normal
saline (NS) were administrated via oral gavage to mice
injected with either the wild type or the mutant HBV for
three times at 24-h intervals. The drug dose was deter-
mined based on the human body dosage and experimen-
tal experience. Mice were sacrificed 4–6 h after the final
administration via oral gavage. Liver tissues were frozen
in liquid nitrogen and stored at −70°C for DNA extrac-
tion and analysis.
Discussion
CHB is one of the most common human infectious dis-
eases worldwide. Infected individuals are at a high risk
of developing liver cirrhosis and HCC [14]. Treatment of
CHB is aimed at suppressing HBV replication, at redu-
cing the accompanying histological inflammation, and at
decreasing the risk of cirrhosis and HCC [15]. Therefore,
antiviral therapies with NAs or interferon are currently
the key treatments for CHB.
However, drug resistance is the major challenge asso-
ciated with long-term therapy with NAs. Drug resistant
HBV mutant strains will gradually become dominant,
which leads to disease deterioration and other serious
consequences. Many studies showed that treatment of
CHB patients with LAM, ADV, or LdT could result inthe emergence of the HBV rtA181T mutant [5,16-18].
Clinically rtA181T is a common resistance mutation to
ADV. This mutation not only induces a decreased sus-
ceptibility to ADV, LAM, and tenofovir [6], but also
encodes S gene mutation. It is reported that the non-
sence mutation at position 172 in the S gene leads to a
55 amino acids truncation of HBsAg. This mutation is
therefore also called HBV rtA181T/sW172*, which may
affect the biological characteristics and pathogenesis of
HBV [4]. However, the biological features of this HBV
mutant in vivo still remain unclear.
Most of recent studies on HBV mutant were done in
cultured cells. Transgenic mice [19,20] are useful models
to study HBV. However, establishing specific transgenic
mice is time and cost consuming. The HBV replication
mouse model that we established with a hydrodynamic-
based procedure is a rapid and convenient alternative,
especially for the characterization of HBV mutations.
We have constructed the rtA181T/sW172* mutant
strain of HBV and investigated its biological characteris-
tics in vivo with our HBV replication mouse model.
Firstly, we found that serum HBsAg level of the
rtA181T/sW172* mutant was very low (OD<0.4) from
day 1 to day 15 after in vivo transfection (Figure 1A),
and that the serum HBV DNA level of the mutant was
lower than that of wild type (Figure 1C). This may be
explained by the fact that the rtA181T/sW172* mutation
causing the production of truncated HBsAg, which can-
not be secreted into the serum. HBsAg plays an import-
ant role in the packaging and secretion of virion [21].
The complete HBV virion consists of an icosahedral nu-
cleocapsid core and an outer lipid envelope, in which
the three envelope proteins [small (S), medium (M) and
large (L)] are anchored as transmembrane proteins play-
ing a major role in HBV morphogenesis and infectivity.
And the mature nucleocapsid enveloped by the surface
proteins can be released to serum [22]. As the S gene
overlaps the P gene completely, the A→T mutation at
position 181 of the P gene in the RT domain replaces
the amino acid tryptophan 172 of the S gene with a ter-
mination codon, resulting in the truncation of the last
55 amino acids. All of the HBV surface proteins (S pro-
tein, M protein, L protein) decrease approximately 6
kDa in molecular weight. These truncated surface pro-
teins may affect the virus assembly and secretion. In this
study, the mostly HBV virions and HBsAg assembled by
these truncated surface proteins may not be secreted
into serum and thus became accumulated in liver. It
seems that the function of the truncated 55 amino acids
in the C-terminal is critical for HBV assembly. The
rtA181T/sW172* mutation thus leads to defects in
the assembly and secretion of HBsAg and virion,
which results in decreased levels of serum HBsAg
and HBV DNA.
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assays targeting the ‘a’ determinant, the highly homolo-
gous region within HBsAg, which is also used as the
main target by hepatitis B vaccines [23]. Recognition of
the ‘a’ determinant by antibody against HBsAg (anti-
HBs) depends on its 3D conformation, which also relies
on the amino acid sequence of the regions flanking the
‘a’ determinant [24]. However, mutants of HBsAg con-
tinue to evolve as a result of vaccine escape, immune se-
lection, and an error prone reverse transcriptase [25].
Because the sW172* mutation of HBsAg gene is not in-
side the ‘a’ determinant, currently commercially antibody
for truncated HBsAg is effective. In addition, the immu-
nohistochemistry results of HBsAg in liver tissue also
supported the effectiveness of conventional antibody for
truncated HBsAg detection. So the low serum HBsAg in
mutant HBV mice model should be due to the intracel-
luar retention of truncated HBsAg. As detection of HBV
DNA in serum is qPCR-based assays, the HBV DNA can
be observed even if it is very little. Compared with the
wild mice, the level of HBV DNA in mutant mice serum
decreased significantly, and these finds were consistent
with the conditions of patients who had the HBV
rtA181T/sW172* mutation.
However, the synthesis and secretion of HBeAg, a
secretory antigen, is regulated differently from HBsAg,
and is regulated by HBV C open reading frame. Serum
HBeAg of two groups showed similar patterns.
Secondly, our study revealed that the expression levels
of HBsAg and HBcAg in liver of mice infected with the
mutant HBV were higher than those of wild type, espe-
cially on day 5 and day 7 (Figure 3). HBsAg, the enve-
lope protein, is normally secreted into serum following
infection. HBcAg, the nucleocapsid protein, is synthe-
sized in infected cells and is required for HBV viral repli-
cation. It seems that the mutant HBV has defects in the
secretion of virions and HBsAg, leading to the accumu-
lation of a large number of viral particles and HBsAg
in liver.
The expression levels of HBV RNA and DNA of the
mutant HBV were higher and lasted longer in liver than
wild type (Figure 2, 3), which may be due to the
increased capability of mutant HBV transcription and
replication . To classify this issue, it is necessary to study
the promoter activity of the mutant HBV in the future
research. As compared to wild type HBV strain, the tran-
scription and replication levels of the HBV rtA181T/
sW172* mutant strain in vivo delayed in reaching the
peak level and lasted significantly longer, and the muta-
tion also was demonstrated HBsAg and HBcAg contin-
ued retention in liver. And these antigens in the liver
tissue may stimulate prolonged immune response. Previ-
ous evidences showed that the adaptive immune re-
sponse should be responsible for viral clearance anddisease pathogenesis during HBV infection [26]. Though
HBV is not directly hepatotoxic [27,28], recent studies
of HBV insertions in HBV-related HCCs revealed that
HBV integration can target the telomerase reverse tran-
scriptase gene, suggesting a potential role for viral inser-
tion in HBV-related carcinogenesis [29-31]. The
cytotoxic T lymphocyte (CTL) not only kills the virus,
but also kills the infected hepatocyte, leading to liver
damage. Persistent infection of HBV is characterized by
chronic liver cell injury, regeneration, inflammation,
widespread DNA damage, cirrhosis of the liver, and
hepatocellular carcinoma [32]. Further studies are on-
going to investigate where and why the secretion of the
mutant HBsAg and HBV virions is impaired, and to ex-
plore the mechanism of mutant HBV accumulation in
liver. The related research will be reported in the future.
Thirdly, cell culture studies have showed that the sin-
gle amino acid substitution at position rt181 in HBV is
the primary resistance mutation to ADV [33] and it also
causes cross resistance to LAM and LdT [6]. The con-
centrations of LAM and LdT for 50% inhibition of HBV
replication (IC50) are 0.023μM and 0.335μM, respect-
ively. Our study found that the folds of decrease in the
sensitivity of the mutant to LAM, ADV, and LdT are dif-
ferent. However, this study utilized 0.022 μM of LAM,
0.0051 μM of ETV and 0.15 μM of LdT in our mouse
models. The corresponding concentration of LAM in
human would be 16.67 times the normal oral dose, that
of ETV would be equivalent to the normal dose, and
that of LdT would have reached 20 times the normal
dose. Oral ADV reduced HBV DNA in both serum and
liver significantly better than LAM, and also worked well
at concentrations as low as 1.0 mg/kg/day [34]. So in
this study, the antiviral effect to HBV rtA181T/sW172*
is ETV>ADV>LAM>LdT. It is related to the establish-
ment method of the mouse model, individual difference
of mice and the drug concentration.
Currently most drug resistance monitoring in clinical
practice is achieved by detecting viral load, not by direct
sequencing. Serum viral load would not be as high as
expected for the kind of variant. This makes us to focus
on the HBV rtA181T/sW172* mutation. If the patient
carries the variation and we failed to change drug in
time, the disease would deteriorate, once rtA181T/
sW172* become the dominant strains. However, the
mouse model used in this study is a transient HBV in-
fection model. The chronic influence of the mutant virus
to mice requires further study.
In conclusion, our results indicated that the rtA181T/
sW172* mutation might impair serum HBsAg secretion
and reduce serum HBV DNA level. However, the tran-
scription and replication levels of the mutant strain in
liver tissues were increased, which may be explained by
the accumulation of viral core particles in liver or the
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clinical consequences of infection by these S gene
mutants demand further clarification. Judicious selection
of antiviral agents and vigilant monitoring of viral
mutants during the course of therapy are advised.
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